Health & Fitness
Fri, October 29, 2010Thu, October 28, 2010Wed, October 27, 2010Tue, October 26, 2010Mon, October 25, 2010Sun, October 24, 2010Sat, October 23, 2010Fri, October 22, 2010Thu, October 21, 2010Wed, October 20, 2010Tue, October 19, 2010Mon, October 18, 2010Sun, October 17, 2010Sat, October 16, 2010Fri, October 15, 2010Thu, October 14, 2010Wed, October 13, 2010Tue, October 12, 2010Mon, October 11, 2010Celera Corporation Third Quarter 2010 Results and Conference Call Scheduled for November 3, 2010
Published in Health and Fitness on Wednesday, October 20th 2010 at 13:25 GMT by Market Wire
ALAMEDA, Calif.--([ BUSINESS WIRE ])--Celera Corporation (NASDAQ:CRA) announced today that it will issue third quarter 2010 financial results on Wednesday, November 3, 2010. Results are scheduled for release after the close of trading on the NASDAQ stock market. Kathy Ordoez, Chief Executive Officer, and Ugo DeBlasi, Chief Financial Officer, will lead a conference call the same day at 4:30 p.m. (ET) to discuss these results and other matters related to the business.
The management team will make prepared remarks and answer questions from securities analysts and investment professionals. Investors, securities analysts, representatives of the media and other interested parties who would like to participate should dial (800) 591-6923, or (617) 614-4907 for international callers, and enter passcode 52178481 at any time from 4:15 p.m. (ET) until the end of the call. This conference call will also be webcast. Interested parties who wish to listen to the webcast should visit the aMedia and Investorsa section on [ www.celera.com ]. A digital recording will be available approximately two hours after the completion of the conference call on November 3 until November 17, 2010. Interested parties should call (888) 286-8010, or (617) 801-6888 for international callers, and enter passcode 38130613.
About Celera
Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at [ http://www.celera.com ].
Copyright© 2010. Celera Corporation. All Rights Reserved. Celera is a registered trademark of Celera Corporation or its subsidiaries in the U. S. and/or certain other countries.
